Nicholas Butowski, MD

Title(s)Professor, Neurological Surgery
SchoolSchool of Medicine
Address400 Parnassus Avenue, #A808
San Francisco CA 94117
Phone415-353-2383
PronounsHe/Him/His
vCardDownload vCard
    Other Positions
    Title(s)UCSF Weill Institute for Neurosciences


    Collapse Biography 
    Collapse Education and Training
    University of California, San Francisco, CA2019Diversity, Equity, and Inclusion Champion Training

    Collapse Overview 
    Collapse Overview
    Dr. Nicholas Butowski is a neuro-oncologist who specializes in brain tumors, neuroimaging, cognitive and rehabilitative neurology, and complementary therapies for neurological disorders. He is director of clinical services in neuro-oncology and a researcher at the Brain Tumor Center.

    In his research, Butowski focuses on developing treatments for primary brain tumors as well as methods to ensure good quality of life for patients and to assist them in recovering from or coping with brain injury.

    Butowski earned his medical degree at the University of Illinois at Chicago. He completed a residency in neurology and a fellowship in neuro-oncology at UCSF. He is a member of the American Academy of Neurology, American Society of Clinical Oncology and Society for Neuro-oncology.

    Collapse Research 
    Collapse Research Activities and Funding
    Advancing treatment and understanding of immunotherapy in glioblastoma
    NIH U19CA264338Sep 10, 2021 - Aug 31, 2026
    Role: Principal Investigator
    A Phase I Study of CED of Liposomal-Irinotecan using imaging in High Grade Glioma
    NIH R21CA186140Apr 1, 2014 - Mar 31, 2017
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Functional prediction of response to therapy prior to therapeutic intervention is associated with improved survival in patients with high-grade glioma. Sci Rep. 2024 08 29; 14(1):19474. Ledford A, Rodriguez A, Lipinski L, Abad A, Fenstermaker R, Edenfield J, Kanos C, Redjal N, Mansouri A, Zacharia B, Butowski N, Liu J, Han SJ, Ziu M, Cohen AL, Fabiano AJ, Miles K, Rayner M, Thompson J, Tollison K, Azimzadeh P, Holmes L, Gevaert M, DesRochers TM. PMID: 39198514.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    2. Fc-enhanced anti-CTLA-4, anti-PD-1, doxorubicin, and ultrasound-mediated BBB opening: A novel combinatorial immunotherapy regimen for gliomas. Neuro Oncol. 2024 Jul 19. Kim KS, Habashy K, Gould A, Zhao J, Najem H, Amidei C, Saganty R, Arrieta VA, Dmello C, Chen L, Zhang DY, Castro B, Billingham L, Levey D, Huber O, Marques M, Savitsky DA, Morin BM, Muzzio M, Canney M, Horbinski C, Zhang P, Miska J, Padney S, Zhang B, Rabadan R, Phillips JJ, Butowski N, Heimberger AB, Hu J, Stupp R, Chand D, Lee-Chang C, Sonabend AM. PMID: 39028616.
      View in: PubMed   Mentions:    Fields:    
    3. NRG-BN002: Phase I Study of Ipilimumab, Nivolumab, and the Combination in Patients with Newly Diagnosed GBM. Neuro Oncol. 2024 Jun 14. Sloan AE, Winter K, Gilbert MR, Aldape K, Choi S, Wen PY, Butowski N, Iwamoto FM, Raval RR, Voloschin AD, Kamiya-Matsuoka C, Won M, Mehta MP. PMID: 38874333.
      View in: PubMed   Mentions:    Fields:    
    4. Automatic Brain Tissue and Lesion Segmentation and Multi-Parametric Mapping of Contrast-Enhancing Gliomas without the Injection of Contrast Agents: A Preliminary Study. Cancers (Basel). 2024 Apr 17; 16(8). Liu J, Jakary A, Villanueva-Meyer JE, Butowski NA, Saloner D, Clarke JL, Taylor JW, Oberheim Bush NA, Chang SM, Xu D, Lupo JM. PMID: 38672606; PMCID: PMC11049314.
      View in: PubMed   Mentions:
    5. A systematic review of high impact CpG sites and regions for MGMT methylation in glioblastoma [A systematic review of MGMT methylation in GBM]. BMC Neurol. 2024 Mar 23; 24(1):103. Gibson D, Vo AH, Lambing H, Bhattacharya P, Tahir P, Chehab FF, Butowski N. PMID: 38521933; PMCID: PMC10960428.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    6. ONC201 (Dordaviprone) in Recurrent H3 K27M-Mutant Diffuse Midline Glioma. J Clin Oncol. 2024 May 01; 42(13):1542-1552. Arrillaga-Romany I, Gardner SL, Odia Y, Aguilera D, Allen JE, Batchelor T, Butowski N, Chen C, Cloughesy T, Cluster A, de Groot J, Dixit KS, Graber JJ, Haggiagi AM, Harrison RA, Kheradpour A, Kilburn LB, Kurz SC, Lu G, MacDonald TJ, Mehta M, Melemed AS, Nghiemphu PL, Ramage SC, Shonka N, Sumrall A, Tarapore RS, Taylor L, Umemura Y, Wen PY. PMID: 38335473; PMCID: PMC11095894.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    7. A combinatory vaccine with IMA950 plus varlilumab promotes effector memory T-cell differentiation in the peripheral blood of patients with low-grade gliomas. Neuro Oncol. 2024 02 02; 26(2):335-347. Saijo A, Ogino H, Butowski NA, Tedesco MR, Gibson D, Watchmaker PB, Okada K, Wang AS, Shai A, Salazar AM, Molinaro AM, Rabbitt JE, Shahin M, Perry A, Clarke JL, Taylor JW, Daras M, Oberheim Bush NA, Hervey-Jumper SL, Phillips JJ, Chang SM, Hilf N, Mayer-Mokler A, Keler T, Berger MS, Okada H. PMID: 37758193; PMCID: PMC10836773.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    8. "De novo replication repair deficient glioblastoma, IDH-wildtype" is a distinct glioblastoma subtype in adults that may benefit from immune checkpoint blockade. Acta Neuropathol. 2023 12 11; 147(1):3. Hadad S, Gupta R, Oberheim Bush NA, Taylor JW, Villanueva-Meyer JE, Young JS, Wu J, Ravindranathan A, Zhang Y, Warrier G, McCoy L, Shai A, Pekmezci M, Perry A, Bollen AW, Phillips JJ, Braunstein SE, Raleigh DR, Theodosopoulos P, Aghi MK, Chang EF, Hervey-Jumper SL, Costello JF, de Groot J, Butowski NA, Clarke JL, Chang SM, Berger MS, Molinaro AM, Solomon DA. PMID: 38079020; PMCID: PMC10713691.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    9. Targeted gene expression profiling predicts meningioma outcomes and radiotherapy responses. Nat Med. 2023 Dec; 29(12):3067-3076. Chen WC, Choudhury A, Youngblood MW, Polley MC, Lucas CG, Mirchia K, Maas SLN, Suwala AK, Won M, Bayley JC, Harmanci AS, Harmanci AO, Klisch TJ, Nguyen MP, Vasudevan HN, McCortney K, Yu TJ, Bhave V, Lam TC, Pu JK, Li LF, Leung GK, Chan JW, Perlow HK, Palmer JD, Haberler C, Berghoff AS, Preusser M, Nicolaides TP, Mawrin C, Agnihotri S, Resnick A, Rood BR, Chew J, Young JS, Boreta L, Braunstein SE, Schulte J, Butowski N, Santagata S, Spetzler D, Bush NAO, Villanueva-Meyer JE, Chandler JP, Solomon DA, Rogers CL, Pugh SL, Mehta MP, Sneed PK, Berger MS, Horbinski CM, McDermott MW, Perry A, Bi WL, Patel AJ, Sahm F, Magill ST, Raleigh DR. PMID: 37944590; PMCID: PMC11073469.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    10. Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways. Cancer Discov. 2023 11 01; 13(11):2370-2393. Venneti S, Kawakibi AR, Ji S, Waszak SM, Sweha SR, Mota M, Pun M, Deogharkar A, Chung C, Tarapore RS, Ramage S, Chi A, Wen PY, Arrillaga-Romany I, Batchelor TT, Butowski NA, Sumrall A, Shonka N, Harrison RA, de Groot J, Mehta M, Hall MD, Daghistani D, Cloughesy TF, Ellingson BM, Beccaria K, Varlet P, Kim MM, Umemura Y, Garton H, Franson A, Schwartz J, Jain R, Kachman M, Baum H, Burant CF, Mottl SL, Cartaxo RT, John V, Messinger D, Qin T, Peterson E, Sajjakulnukit P, Ravi K, Waugh A, Walling D, Ding Y, Xia Z, Schwendeman A, Hawes D, Yang F, Judkins AR, Wahl D, Lyssiotis CA, de la Nava D, Alonso MM, Eze A, Spitzer J, Schmidt SV, Duchatel RJ, Dun MD, Cain JE, Jiang L, Stopka SA, Baquer G, Regan MS, Filbin MG, Agar NYR, Zhao L, Kumar-Sinha C, Mody R, Chinnaiyan A, Kurokawa R, Pratt D, Yadav VN, Grill J, Kline C, Mueller S, Resnick A, Nazarian J, Allen JE, Odia Y, Gardner SL, Koschmann C. PMID: 37584601; PMCID: PMC10618742.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    11. Quantitative analysis of MGMT promoter methylation in glioblastoma suggests nonlinear prognostic effect. Neurooncol Adv. 2023 Jan-Dec; 5(1):vdad115. Gibson D, Ravi A, Rodriguez E, Chang S, Oberheim Bush N, Taylor J, Clarke J, Solomon D, Scheffler A, Witte J, Lambing H, Okada H, Berger M, Chehab F, Butowski NA. PMID: 37899778; PMCID: PMC10611422.
      View in: PubMed   Mentions: 1  
    12. A multicenter, phase 1, dose escalation clinical trial (G-FORCE-1) of XRT, RRx-001 and temozolomide followed by temozolomide +/- RRx-001 in newly diagnosed glioblastoma. Front Oncol. 2023; 13:1176448. Fine H, Reid T, Caroen S, Oronsky B, Abrouk N, Butowski N. PMID: 37342189; PMCID: PMC10277641.
      View in: PubMed   Mentions: 3  
    13. Targeting the IL4 receptor with MDNA55 in patients with recurrent glioblastoma: Results of a phase IIb trial. Neuro Oncol. 2023 06 02; 25(6):1085-1097. Sampson JH, Singh Achrol A, Aghi MK, Bankiewicz K, Bexon M, Brem S, Brenner A, Chandhasin C, Chowdhary S, Coello M, Ellingson BM, Floyd JR, Han S, Kesari S, Mardor Y, Merchant F, Merchant N, Randazzo D, Vogelbaum M, Vrionis F, Wembacher-Schroeder E, Zabek M, Butowski N. PMID: 36640127; PMCID: PMC10237418.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    14. Targeted gene expression profiling predicts meningioma outcomes and radiotherapy responses. Res Sq. 2023 Mar 20. Raleigh D, Chen W, Choudhury A, Youngblood M, Polley MY, Lucas CH, Mirchia K, Maas S, Suwala A, Won M, Bayley J, Harmanci A, Harmanci A, Klisch T, Nguyen M, Vasudevan H, McCortney K, Yu T, Bhave V, Lam TC, Pu J, Leung G, Chang J, Perlow H, Palmer J, Haberler C, Berghoff A, Preusser M, Nicolaides T, Mawrin C, Agnihotri S, Resnick A, Rood B, Chew J, Young J, Boreta L, Braunstein S, Schulte J, Butowski N, Santagata S, Spetzler D, Bush NAO, Villanueva-Meyer J, Chandler J, Solomon D, Rogers C, Pugh S, Mehta M, Sneed P, Berger M, Horbinski C, McDermott M, Perry A, Bi W, Patel A, Sahm F, Magill S. PMID: 36993741; PMCID: PMC10055655.
      View in: PubMed   Mentions: 1  
    15. Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial. Neuro Oncol. 2023 01 05; 25(1):123-134. Omuro A, Brandes AA, Carpentier AF, Idbaih A, Reardon DA, Cloughesy T, Sumrall A, Baehring J, van den Bent M, Bähr O, Lombardi G, Mulholland P, Tabatabai G, Lassen U, Sepulveda JM, Khasraw M, Vauleon E, Muragaki Y, Di Giacomo AM, Butowski N, Roth P, Qian X, Fu AZ, Liu Y, Potter V, Chalamandaris AG, Tatsuoka K, Lim M, Weller M. PMID: 35419607; PMCID: PMC9825306.
      View in: PubMed   Mentions: 117     Fields:    Translation:HumansCTClinical Trials
    16. Recent advances in the molecular prognostication of meningiomas. Front Oncol. 2022; 12:910199. Wang EJ, Haddad AF, Young JS, Morshed RA, Wu JPH, Salha DM, Butowski N, Aghi MK. PMID: 36686824; PMCID: PMC9845914.
      View in: PubMed   Mentions: 1  
    17. Interactive Effects of Molecular, Therapeutic, and Patient Factors on Outcome of Diffuse Low-Grade Glioma. J Clin Oncol. 2023 04 10; 41(11):2029-2042. Hervey-Jumper SL, Zhang Y, Phillips JJ, Morshed RA, Young JS, McCoy L, Lafontaine M, Luks T, Ammanuel S, Kakaizada S, Egladyous A, Gogos A, Villanueva-Meyer J, Shai A, Warrier G, Rice T, Crane J, Wrensch M, Wiencke JK, Daras M, Oberheim Bush NA, Taylor JW, Butowski N, Clarke J, Chang S, Chang E, Aghi M, Theodosopoulos P, McDermott M, Jakola AS, Kavouridis VK, Nawabi N, Solheim O, Smith T, Berger MS, Molinaro AM. PMID: 36599113; PMCID: PMC10082290.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    18. Therapeutic and Supportive Effects of Cannabinoids in Patients with Brain Tumors (CBD Oil and Cannabis). Curr Treat Options Oncol. 2023 01; 24(1):30-44. Rodriguez-Almaraz JE, Butowski N. PMID: 36633803; PMCID: PMC9867687.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimals
    19. NCCN Guidelines® Insights: Central Nervous System Cancers, Version 2.2022. J Natl Compr Canc Netw. 2023 01; 21(1):12-20. Horbinski C, Nabors LB, Portnow J, Baehring J, Bhatia A, Bloch O, Brem S, Butowski N, Cannon DM, Chao S, Chheda MG, Fabiano AJ, Forsyth P, Gigilio P, Hattangadi-Gluth J, Holdhoff M, Junck L, Kaley T, Merrell R, Mrugala MM, Nagpal S, Nedzi LA, Nevel K, Nghiemphu PL, Parney I, Patel TR, Peters K, Puduvalli VK, Rockhill J, Rusthoven C, Shonka N, Swinnen LJ, Weiss S, Wen PY, Willmarth NE, Bergman MA, Darlow S. PMID: 36634606.
      View in: PubMed   Mentions: 34     Fields:    Translation:Humans
    20. Novel intraoperative strategies for enhancing tumor control: Future directions. Neuro Oncol. 2022 11 02; 24(Suppl 6):S25-S32. Haddad AF, Aghi MK, Butowski N. PMID: 36322096; PMCID: PMC9629473.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    21. Prospective genomically guided identification of "early/evolving" and "undersampled" IDH-wildtype glioblastoma leads to improved clinical outcomes. Neuro Oncol. 2022 10 03; 24(10):1749-1762. Zhang Y, Lucas CG, Young JS, Morshed RA, McCoy L, Oberheim Bush NA, Taylor JW, Daras M, Butowski NA, Villanueva-Meyer JE, Cha S, Wrensch M, Wiencke JK, Lee JC, Pekmezci M, Phillips JJ, Perry A, Bollen AW, Aghi MK, Theodosopoulos P, Chang EF, Hervey-Jumper SL, Berger MS, Clarke JL, Chang SM, Molinaro AM, Solomon DA. PMID: 35395677; PMCID: PMC9527525.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    22. Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1. Acta Neuropathol. 2022 10; 144(4):747-765. Lucas CG, Sloan EA, Gupta R, Wu J, Pratt D, Vasudevan HN, Ravindranathan A, Barreto J, Williams EA, Shai A, Whipple NS, Bruggers CS, Maher O, Nabors B, Rodriguez M, Samuel D, Brown M, Carmichael J, Lu R, Mirchia K, Sullivan DV, Pekmezci M, Tihan T, Bollen AW, Perry A, Banerjee A, Mueller S, Gupta N, Hervey-Jumper SL, Oberheim Bush NA, Daras M, Taylor JW, Butowski NA, de Groot J, Clarke JL, Raleigh DR, Costello JF, Phillips JJ, Reddy AT, Chang SM, Berger MS, Solomon DA. PMID: 35945463; PMCID: PMC9468105.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    23. CDK 4/6 inhibitors for the treatment of meningioma. Front Oncol. 2022; 12:931371. Young JS, Kidwell RL, Zheng A, Haddad AF, Aghi MK, Raleigh DR, Schulte JD, Butowski NA. PMID: 35936751; PMCID: PMC9354681.
      View in: PubMed   Mentions: 6  
    24. Intratumor and informatic heterogeneity influence meningioma molecular classification. Acta Neuropathol. 2022 09; 144(3):579-583. Vasudevan HN, Choudhury A, Hilz S, Villanueva-Meyer JE, Chen WC, Lucas CG, Braunstein SE, Oberheim Bush NA, Butowski N, Pekmezci M, McDermott MW, Perry A, Solomon DA, Magill ST, Raleigh DR. PMID: 35759011; PMCID: PMC9618384.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    25. Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study. Clin Cancer Res. 2022 06 01; 28(11):2270-2277. Lassman AB, Sepúlveda-Sánchez JM, Cloughesy TF, Gil-Gil MJ, Puduvalli VK, Raizer JJ, De Vos FYF, Wen PY, Butowski NA, Clement PMJ, Groves MD, Belda-Iniesta C, Giglio P, Soifer HS, Rowsey S, Xu C, Avogadri F, Wei G, Moran S, Roth P. PMID: 35344029; PMCID: PMC9167702.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCTClinical Trials
    26. Meningioma DNA methylation groups identify biological drivers and therapeutic vulnerabilities. Nat Genet. 2022 05; 54(5):649-659. Choudhury A, Magill ST, Eaton CD, Prager BC, Chen WC, Cady MA, Seo K, Lucas CG, Casey-Clyde TJ, Vasudevan HN, Liu SJ, Villanueva-Meyer JE, Lam TC, Pu JK, Li LF, Leung GK, Swaney DL, Zhang MY, Chan JW, Qiu Z, Martin MV, Susko MS, Braunstein SE, Bush NAO, Schulte JD, Butowski N, Sneed PK, Berger MS, Krogan NJ, Perry A, Phillips JJ, Solomon DA, Costello JF, McDermott MW, Rich JN, Raleigh DR. PMID: 35534562; PMCID: PMC9374001.
      View in: PubMed   Mentions: 81     Fields:    Translation:HumansCells
    27. Phase I/randomized phase II trial of TRC105 plus bevacizumab versus bevacizumab in recurrent glioblastoma: North Central Cancer Treatment Group N1174 (Alliance). Neurooncol Adv. 2022 Jan-Dec; 4(1):vdac041. Galanis E, Anderson SK, Twohy E, Butowski NA, Hormigo A, Schiff D, Omuro A, Jaeckle KA, Kumar S, Kaufmann TJ, Geyer S, Kumthekar PU, Campian J, Giannini C, Buckner JC, Wen PY. PMID: 35664553; PMCID: PMC9154335.
      View in: PubMed   Mentions: 4  
    28. Nivolumab plus radiotherapy with or without temozolomide in newly diagnosed glioblastoma: Results from exploratory phase I cohorts of CheckMate 143. Neurooncol Adv. 2022 Jan-Dec; 4(1):vdac025. Omuro A, Reardon DA, Sampson JH, Baehring J, Sahebjam S, Cloughesy TF, Chalamandaris AG, Potter V, Butowski N, Lim M. PMID: 35402913; PMCID: PMC8989388.
      View in: PubMed   Mentions: 21  
    29. Randomized trial of neoadjuvant vaccination with tumor-cell lysate induces T cell response in low-grade gliomas. J Clin Invest. 2022 02 01; 132(3). Ogino H, Taylor JW, Nejo T, Gibson D, Watchmaker PB, Okada K, Saijo A, Tedesco MR, Shai A, Wong CM, Rabbitt JE, Olin MR, Moertel CL, Nishioka Y, Salazar AM, Molinaro AM, Phillips JJ, Butowski NA, Clarke JL, Oberheim Bush NA, Hervey-Jumper SL, Theodosopoulos P, Chang SM, Berger MS, Okada H. PMID: 34882581; PMCID: PMC8803342.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCellsPHPublic Health
    30. Association of Neurological Impairment on the Relative Benefit of Maximal Extent of Resection in Chemoradiation-Treated Newly Diagnosed Isocitrate Dehydrogenase Wild-Type Glioblastoma. Neurosurgery. 2022 01 01; 90(1):124-130. Aabedi AA, Young JS, Zhang Y, Ammanuel S, Morshed RA, Dalle Ore C, Brown D, Phillips JJ, Oberheim Bush NA, Taylor JW, Butowski N, Clarke J, Chang SM, Aghi M, Molinaro AM, Berger MS, Hervey-Jumper SL. PMID: 34982879; PMCID: PMC9514750.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    31. Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade IDH-mutant gliomas. Neuro Oncol. 2021 11 02; 23(11):1872-1884. Yu Y, Villanueva-Meyer J, Grimmer MR, Hilz S, Solomon DA, Choi S, Wahl M, Mazor T, Hong C, Shai A, Phillips JJ, Wainer BH, McDermott M, Haas-Kogan D, Taylor JW, Butowski N, Clarke JL, Berger MS, Molinaro AM, Chang SM, Costello JF, Oberheim Bush NA. PMID: 33823014; PMCID: PMC8563321.
      View in: PubMed   Mentions: 37     Fields:    Translation:Humans
    32. Mouse models of glioblastoma for the evaluation of novel therapeutic strategies. Neurooncol Adv. 2021 Jan-Dec; 3(1):vdab100. Haddad AF, Young JS, Amara D, Berger MS, Raleigh DR, Aghi MK, Butowski NA. PMID: 34466804; PMCID: PMC8403483.
      View in: PubMed   Mentions: 50  
    33. Validation of diffusion MRI as a biomarker for efficacy using randomized phase III trial of bevacizumab with or without VB-111 in recurrent glioblastoma. Neurooncol Adv. 2021 Jan-Dec; 3(1):vdab082. Ellingson BM, Patel K, Wang C, Raymond C, Brenner A, de Groot JF, Butowski NA, Zach L, Campian JL, Schlossman J, Rizvi S, Cohen YC, Lowenton-Spier N, Minei TR, Shmueli SF, Wen PY, Cloughesy TF. PMID: 34377989; PMCID: PMC8350152.
      View in: PubMed   Mentions: 2  
    34. A single institution retrospective analysis on survival based on treatment paradigms for patients with anaplastic oligodendroglioma. J Neurooncol. 2021 Jul; 153(3):447-454. Bush NAO, Young JS, Zhang Y, Dalle Ore CL, Molinaro AM, Taylor J, Clarke J, Prados M, Braunstein SE, Raleigh DR, Chang SM, Berger MS, Butowski NA. PMID: 34125374; PMCID: PMC8279971.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    35. Prospective prediction of clinical drug response in high-grade gliomas using an ex vivo 3D cell culture assay. Neurooncol Adv. 2021 Jan-Dec; 3(1):vdab065. Shuford S, Lipinski L, Abad A, Smith AM, Rayner M, O'Donnell L, Stuart J, Mechtler LL, Fabiano AJ, Edenfield J, Kanos C, Gardner S, Hodge P, Lynn M, Butowski NA, Han SJ, Redjal N, Crosswell HE, Vibat CRT, Holmes L, Gevaert M, Fenstermaker RA, DesRochers TM. PMID: 34142085; PMCID: PMC8207705.
      View in: PubMed   Mentions: 12  
    36. Modified RANO, Immunotherapy RANO, and Standard RANO Response to Convection-Enhanced Delivery of IL4R-Targeted Immunotoxin MDNA55 in Recurrent Glioblastoma. Clin Cancer Res. 2021 07 15; 27(14):3916-3925. Ellingson BM, Sampson J, Achrol AS, Aghi MK, Bankiewicz K, Wang C, Bexon M, Brem S, Brenner A, Chowdhary S, Floyd JR, Han S, Kesari S, Randazzo D, Vogelbaum MA, Vrionis F, Zabek M, Butowski N, Coello M, Merchant N, Merchant F. PMID: 33863808; PMCID: PMC8282697.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCTClinical Trials
    37. The state of neuro-oncology during the COVID-19 pandemic: a worldwide assessment. Neurooncol Adv. 2021 Jan-Dec; 3(1):vdab035. Mrugala MM, Ostrom QT, Pressley SM, Taylor JW, Thomas AA, Wefel JS, Coven SL, Acquaye AA, Haynes C, Agnihotri S, Lim M, Peters KB, Sulman EP, Salcido JT, Butowski NA, Hervey-Jumper S, Mansouri A, Oliver KR, Porter AB, Nassiri F, Schiff D, Dunbar EM, Hegi ME, Armstrong TS, van den Bent MJ, Chang SM, Zadeh G, Chheda MG. PMID: 34007966; PMCID: PMC7928618.
      View in: PubMed   Mentions: 8  
    38. Effect of Vocimagene Amiretrorepvec in Combination With Flucytosine vs Standard of Care on Survival Following Tumor Resection in Patients With Recurrent High-Grade Glioma: A Randomized Clinical Trial. JAMA Oncol. 2020 12 01; 6(12):1939-1946. Cloughesy TF, Petrecca K, Walbert T, Butowski N, Salacz M, Perry J, Damek D, Bota D, Bettegowda C, Zhu JJ, Iwamoto F, Placantonakis D, Kim L, Elder B, Kaptain G, Cachia D, Moshel Y, Brem S, Piccioni D, Landolfi J, Chen CC, Gruber H, Rao AR, Hogan D, Accomando W, Ostertag D, Montellano TT, Kheoh T, Kabbinavar F, Vogelbaum MA. PMID: 33119048; PMCID: PMC7596685.
      View in: PubMed   Mentions: 61     Fields:    Translation:Humans
    39. Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020 11 02; 18(11):1537-1570. Nabors LB, Portnow J, Ahluwalia M, Baehring J, Brem H, Brem S, Butowski N, Campian JL, Clark SW, Fabiano AJ, Forsyth P, Hattangadi-Gluth J, Holdhoff M, Horbinski C, Junck L, Kaley T, Kumthekar P, Loeffler JS, Mrugala MM, Nagpal S, Pandey M, Parney I, Peters K, Puduvalli VK, Robins I, Rockhill J, Rusthoven C, Shonka N, Shrieve DC, Swinnen LJ, Weiss S, Wen PY, Willmarth NE, Bergman MA, Darlow SD. PMID: 33152694.
      View in: PubMed   Mentions: 188     Fields:    Translation:Humans
    40. Clinical, radiologic, and genetic characteristics of histone H3 K27M-mutant diffuse midline gliomas in adults. Neurooncol Adv. 2020 Jan-Dec; 2(1):vdaa142. Schulte JD, Buerki RA, Lapointe S, Molinaro AM, Zhang Y, Villanueva-Meyer JE, Perry A, Phillips JJ, Tihan T, Bollen AW, Pekmezci M, Butowski N, Oberheim Bush NA, Taylor JW, Chang SM, Theodosopoulos P, Aghi MK, Hervey-Jumper SL, Berger MS, Solomon DA, Clarke JL. PMID: 33354667; PMCID: PMC7739048.
      View in: PubMed   Mentions: 37  
    41. The immunohistochemical, DNA methylation, and chromosomal copy number profile of cauda equina paraganglioma is distinct from extra-spinal paraganglioma. Acta Neuropathol. 2020 12; 140(6):907-917. Ramani B, Gupta R, Wu J, Barreto J, Bollen AW, Tihan T, Mummaneni PV, Ames C, Clark A, Oberheim Bush NA, Butowski N, Phillips D, King BE, Bator SM, Treynor EC, Zherebitskiy V, Quinn PS, Walker JB, Pekmezci M, Sullivan DV, Hofmann JW, Sloan EA, M Chang S, Berger MS, Solomon DA, Perry A. PMID: 32892244; PMCID: PMC7682537.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    42. Comprehensive analysis of diverse low-grade neuroepithelial tumors with FGFR1 alterations reveals a distinct molecular signature of rosette-forming glioneuronal tumor. Acta Neuropathol Commun. 2020 08 28; 8(1):151. Lucas CG, Gupta R, Doo P, Lee JC, Cadwell CR, Ramani B, Hofmann JW, Sloan EA, Kleinschmidt-DeMasters BK, Lee HS, Wood MD, Grafe M, Born D, Vogel H, Salamat S, Puccetti D, Scharnhorst D, Samuel D, Cooney T, Cham E, Jin LW, Khatib Z, Maher O, Chamyan G, Brathwaite C, Bannykh S, Mueller S, Kline CN, Banerjee A, Reddy A, Taylor JW, Clarke JL, Oberheim Bush NA, Butowski N, Gupta N, Auguste KI, Sun PP, Roland JL, Raffel C, Aghi MK, Theodosopoulos P, Chang E, Hervey-Jumper S, Phillips JJ, Pekmezci M, Bollen AW, Tihan T, Chang S, Berger MS, Perry A, Solomon DA. PMID: 32859279; PMCID: PMC7456392.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    43. A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE). Neuro Oncol. 2020 05 15; 22(5):705-717. Cloughesy TF, Brenner A, de Groot JF, Butowski NA, Zach L, Campian JL, Ellingson BM, Freedman LS, Cohen YC, Lowenton-Spier N, Rachmilewitz Minei T, Fain Shmueli S, GLOBE Study Investigators, Wen PY. PMID: 31844890; PMCID: PMC7229248.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansCTClinical Trials
    44. The influence of race and socioeconomic status on therapeutic clinical trial screening and enrollment. J Neurooncol. 2020 May; 148(1):131-139. Morshed RA, Reihl SJ, Molinaro AM, Kakaizada S, Young JS, Schulte JD, Butowski N, Taylor J, Bush NA, Aghi MK, Berger MS, Chang S, Clarke J, Hervey-Jumper SL. PMID: 32350780.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    45. A systematic review and meta-analysis examining the effects of cannabis and its derivatives in adults with malignant CNS tumors. Neurooncol Pract. 2020 Jul; 7(4):376-383. Rodriguez-Almaraz JE, Chang S, Clarke J, Oberheim-Bush NA, Taylor J, Buerki R, Berger M, Zablotska L, Lobach I, Butowski N. PMID: 32765889; PMCID: PMC7393278.
      View in: PubMed   Mentions: 4  
    46. Association of Maximal Extent of Resection of Contrast-Enhanced and Non-Contrast-Enhanced Tumor With Survival Within Molecular Subgroups of Patients With Newly Diagnosed Glioblastoma. JAMA Oncol. 2020 04 01; 6(4):495-503. Molinaro AM, Hervey-Jumper S, Morshed RA, Young J, Han SJ, Chunduru P, Zhang Y, Phillips JJ, Shai A, Lafontaine M, Crane J, Chandra A, Flanigan P, Jahangiri A, Cioffi G, Ostrom Q, Anderson JE, Badve C, Barnholtz-Sloan J, Sloan AE, Erickson BJ, Decker PA, Kosel ML, LaChance D, Eckel-Passow J, Jenkins R, Villanueva-Meyer J, Rice T, Wrensch M, Wiencke JK, Oberheim Bush NA, Taylor J, Butowski N, Prados M, Clarke J, Chang S, Chang E, Aghi M, Theodosopoulos P, McDermott M, Berger MS. PMID: 32027343; PMCID: PMC7042822.
      View in: PubMed   Mentions: 193     Fields:    Translation:HumansCells
    47. Recurrent non-canonical histone H3 mutations in spinal cord diffuse gliomas. Acta Neuropathol. 2019 11; 138(5):877-881. Sloan EA, Cooney T, Oberheim Bush NA, Buerki R, Taylor J, Clarke JL, Torkildson J, Kline C, Reddy A, Mueller S, Banerjee A, Butowski N, Chang S, Mummaneni PV, Chou D, Tan L, Theodosopoulos P, McDermott M, Berger M, Raffel C, Gupta N, Sun PP, Li Y, Shah V, Cha S, Braunstein S, Raleigh DR, Samuel D, Scharnhorst D, Fata C, Guo H, Moes G, Kim JYH, Koschmann C, Van Ziffle J, Onodera C, Devine P, Grenert JP, Lee JC, Pekmezci M, Phillips JJ, Tihan T, Bollen AW, Perry A, Solomon DA. PMID: 31515627; PMCID: PMC6818961.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    48. Editorial. Chronic convection-enhanced delivery: the next frontier in regional drug infusion for glioblastoma. J Neurosurg. 2019 Aug 02; 133(3):611-613. Butowski NA, Bringas JR, Bankiewicz KS, Aghi MK. PMID: 31374552.
      View in: PubMed   Mentions:    Fields:    
    49. Reirradiation of recurrent high-grade glioma and development of prognostic scores for progression and survival. Neurooncol Pract. 2019 Sep; 6(5):364-374. Chapman CH, Hara JH, Molinaro AM, Clarke JL, Oberheim Bush NA, Taylor JW, Butowski NA, Chang SM, Fogh SE, Sneed PK, Nakamura JL, Raleigh DR, Braunstein SE. PMID: 31555451; PMCID: PMC6753361.
      View in: PubMed   Mentions: 15  
    50. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat Med. 2019 03; 25(3):477-486. Cloughesy TF, Mochizuki AY, Orpilla JR, Hugo W, Lee AH, Davidson TB, Wang AC, Ellingson BM, Rytlewski JA, Sanders CM, Kawaguchi ES, Du L, Li G, Yong WH, Gaffey SC, Cohen AL, Mellinghoff IK, Lee EQ, Reardon DA, O'Brien BJ, Butowski NA, Nghiemphu PL, Clarke JL, Arrillaga-Romany IC, Colman H, Kaley TJ, de Groot JF, Liau LM, Wen PY, Prins RM. PMID: 30742122; PMCID: PMC6408961.
      View in: PubMed   Mentions: 626     Fields:    Translation:HumansCells
    51. Risk factors of radiotherapy-induced cerebral microbleeds and serial analysis of their size compared with white matter changes: A 7T MRI study in 113 adult patients with brain tumors. J Magn Reson Imaging. 2019 09; 50(3):868-877. Morrison MA, Hess CP, Clarke JL, Butowski N, Chang SM, Molinaro AM, Lupo JM. PMID: 30663150; PMCID: PMC6642688.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansPHPublic Health
    52. Advances in multidisciplinary therapy for meningiomas. Neuro Oncol. 2019 01 14; 21(Suppl 1):i18-i31. Brastianos PK, Galanis E, Butowski N, Chan JW, Dunn IF, Goldbrunner R, Herold-Mende C, Ippen FM, Mawrin C, McDermott MW, Sloan A, Snyder J, Tabatabai G, Tatagiba M, Tonn JC, Wen PY, Aldape K, Nassiri F, Zadeh G, Jenkinson MD, Raleigh DR, International Consortium on Meningiomas. PMID: 30649489; PMCID: PMC6347080.
      View in: PubMed   Mentions: 74     Fields:    Translation:Humans
    53. Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial. Neuro Oncol. 2019 01 01; 21(1):106-114. Lassman AB, van den Bent MJ, Gan HK, Reardon DA, Kumthekar P, Butowski N, Lwin Z, Mikkelsen T, Nabors LB, Papadopoulos KP, Penas-Prado M, Simes J, Wheeler H, Walbert T, Scott AM, Gomez E, Lee HJ, Roberts-Rapp L, Xiong H, Ansell PJ, Bain E, Holen KD, Maag D, Merrell R. PMID: 29982805; PMCID: PMC6303422.
      View in: PubMed   Mentions: 60     Fields:    Translation:HumansCTClinical Trials
    54. Molecular features and clinical outcomes in surgically treated low-grade diffuse gliomas in patients over the age of 60. J Neurooncol. 2019 Jan; 141(2):383-391. Morshed RA, Han SJ, Hervey-Jumper SL, Pekmezci M, Troncon I, Chang SM, Butowski NA, Berger MS. PMID: 30498891.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    55. Attitudes toward fertility and fertility preservation in women with glioma. Neurooncol Pract. 2019 May; 6(3):218-225. Stiner RK, Clarke JL, Sinha N, Chan J, Letourneau JM, Niemasik EE, Rabbitt JE, Chang SM, Butowski NA, Prados MD, Rosen MP. PMID: 31386027; PMCID: PMC6656302.
      View in: PubMed   Mentions: 4  
    56. Using genomics to guide treatment for glioblastoma. Pharmacogenomics. 2018 10; 19(15):1217-1229. Young JS, Prados MD, Butowski N. PMID: 30203716.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimalsCells
    57. The genetic landscape of gliomas arising after therapeutic radiation. Acta Neuropathol. 2019 01; 137(1):139-150. López GY, Van Ziffle J, Onodera C, Grenert JP, Yeh I, Bastian BC, Clarke J, Oberheim Bush NA, Taylor J, Chang S, Butowski N, Banerjee A, Mueller S, Kline C, Torkildson J, Samuel D, Siongco A, Raffel C, Gupta N, Kunwar S, Mummaneni P, Aghi M, Theodosopoulos P, Berger M, Phillips JJ, Pekmezci M, Tihan T, Bollen AW, Perry A, Solomon DA. PMID: 30196423; PMCID: PMC6589431.
      View in: PubMed   Mentions: 39     Fields:    Translation:Humans
    58. Phase-2 trial of palbociclib in adult patients with recurrent RB1-positive glioblastoma. J Neurooncol. 2018 Nov; 140(2):477-483. Taylor JW, Parikh M, Phillips JJ, James CD, Molinaro AM, Butowski NA, Clarke JL, Oberheim-Bush NA, Chang SM, Berger MS, Prados M. PMID: 30151703; PMCID: PMC6239922.
      View in: PubMed   Mentions: 59     Fields:    Translation:HumansCTClinical Trials
    59. Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma. Neuro Oncol. 2018 08 02; 20(9):1240-1250. Ellingson BM, Abrey LE, Nelson SJ, Kaufmann TJ, Garcia J, Chinot O, Saran F, Nishikawa R, Henriksson R, Mason WP, Wick W, Butowski N, Ligon KL, Gerstner ER, Colman H, de Groot J, Chang S, Mellinghoff I, Young RJ, Alexander BM, Colen R, Taylor JW, Arrillaga-Romany I, Mehta A, Huang RY, Pope WB, Reardon D, Batchelor T, Prados M, Galanis E, Wen PY, Cloughesy TF. PMID: 29660006; PMCID: PMC6071654.
      View in: PubMed   Mentions: 41     Fields:    Translation:HumansCTClinical Trials
    60. Primary brain tumours in adults. Lancet. 2018 08 04; 392(10145):432-446. Lapointe S, Perry A, Butowski NA. PMID: 30060998.
      View in: PubMed   Mentions: 585     Fields:    Translation:Humans
    61. Novel and Prospective Molecular Targets for Therapy of Intracranial Gliomas. Prog Neurol Surg. 2018; 32:66-78. Butowski N. PMID: 29990975.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    62. Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma. Neuro Oncol. 2018 05 18; 20(6):838-847. Gan HK, Reardon DA, Lassman AB, Merrell R, van den Bent M, Butowski N, Lwin Z, Wheeler H, Fichtel L, Scott AM, Gomez EJ, Fischer J, Mandich H, Xiong H, Lee HJ, Munasinghe WP, Roberts-Rapp LA, Ansell PJ, Holen KD, Kumthekar P. PMID: 29077941; PMCID: PMC5961429.
      View in: PubMed   Mentions: 41     Fields:    Translation:HumansCTClinical Trials
    63. A recurrent kinase domain mutation in PRKCA defines chordoid glioma of the third ventricle. Nat Commun. 2018 02 23; 9(1):810. Goode B, Mondal G, Hyun M, Ruiz DG, Lin YH, Van Ziffle J, Joseph NM, Onodera C, Talevich E, Grenert JP, Hewedi IH, Snuderl M, Brat DJ, Kleinschmidt-DeMasters BK, Rodriguez FJ, Louis DN, Yong WH, Lopes MB, Rosenblum MK, Butowski N, Tihan T, Bollen AW, Phillips JJ, Wiita AP, Yeh I, Jacobson MP, Bastian BC, Perry A, Solomon DA. PMID: 29476136; PMCID: PMC5824822.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCells
    64. MRI Features and IDH Mutational Status of Grade II Diffuse Gliomas: Impact on Diagnosis and Prognosis. AJR Am J Roentgenol. 2018 Mar; 210(3):621-628. Villanueva-Meyer JE, Wood MD, Choi BS, Mabray MC, Butowski NA, Tihan T, Cha S. PMID: 29261348; PMCID: PMC5823758.
      View in: PubMed   Mentions: 33     Fields:    Translation:Humans
    65. Go, no-go decision making for phase 3 clinical trials: ACT IV revisited - Authors' reply. Lancet Oncol. 2017 12; 18(12):e709-e710. Weller M, Butowski N, Tran DD, Recht LD, Lim M, Hirte H, Ashby L, Mechtler L, Goldlust SA, Iwamoto F, Drappatz J, O'Rourke DM, Wong M, Hamilton MG, Finocchiaro G, Perry J, Wick W, Green J, He Y, Turner CD, Yellin MJ, Keler T, Davis TA, Stupp R, Sampson JH. PMID: 29208433.
      View in: PubMed   Mentions: 2     Fields:    
    66. NCCN Guidelines Insights: Central Nervous System Cancers, Version 1.2017. J Natl Compr Canc Netw. 2017 11; 15(11):1331-1345. Nabors LB, Portnow J, Ammirati M, Baehring J, Brem H, Butowski N, Fenstermaker RA, Forsyth P, Hattangadi-Gluth J, Holdhoff M, Howard S, Junck L, Kaley T, Kumthekar P, Loeffler JS, Moots PL, Mrugala MM, Nagpal S, Pandey M, Parney I, Peters K, Puduvalli VK, Ragsdale J, Rockhill J, Rogers L, Rusthoven C, Shonka N, Shrieve DC, Sills AK, Swinnen LJ, Tsien C, Weiss S, Wen PY, Willmarth N, Bergman MA, Engh A. PMID: 29118226.
      View in: PubMed   Mentions: 97     Fields:    Translation:Humans
    67. Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study. Cancer Chemother Pharmacol. 2017 Dec; 80(6):1209-1217. van den Bent M, Gan HK, Lassman AB, Kumthekar P, Merrell R, Butowski N, Lwin Z, Mikkelsen T, Nabors LB, Papadopoulos KP, Penas-Prado M, Simes J, Wheeler H, Walbert T, Scott AM, Gomez E, Lee HJ, Roberts-Rapp L, Xiong H, Bain E, Ansell PJ, Holen KD, Maag D, Reardon DA. PMID: 29075855; PMCID: PMC5686264.
      View in: PubMed   Mentions: 70     Fields:    Translation:HumansCTClinical Trials
    68. Prospective Feasibility Trial for Genomics-Informed Treatment in Recurrent and Progressive Glioblastoma. Clin Cancer Res. 2018 01 15; 24(2):295-305. Byron SA, Tran NL, Halperin RF, Phillips JJ, Kuhn JG, de Groot JF, Colman H, Ligon KL, Wen PY, Cloughesy TF, Mellinghoff IK, Butowski NA, Taylor JW, Clarke JL, Chang SM, Berger MS, Molinaro AM, Maggiora GM, Peng S, Nasser S, Liang WS, Trent JM, Berens ME, Carpten JD, Craig DW, Prados MD. PMID: 29074604; PMCID: PMC7516926.
      View in: PubMed   Mentions: 34     Fields:    Translation:Humans
    69. Familial melanoma-astrocytoma syndrome: synchronous diffuse astrocytoma and pleomorphic xanthoastrocytoma in a patient with germline CDKN2A/B deletion and a significant family history. Clin Neuropathol. 2017 Sep/Oct; 36(5):213-221. Chan AK, Han SJ, Choy W, Beleford D, Aghi MK, Berger MS, Shieh JT, Bollen AW, Perry A, Phillips JJ, Butowski N, Solomon DA. PMID: 28699883; PMCID: PMC5628627.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    70. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. Lancet Oncol. 2017 10; 18(10):1373-1385. Weller M, Butowski N, Tran DD, Recht LD, Lim M, Hirte H, Ashby L, Mechtler L, Goldlust SA, Iwamoto F, Drappatz J, O'Rourke DM, Wong M, Hamilton MG, Finocchiaro G, Perry J, Wick W, Green J, He Y, Turner CD, Yellin MJ, Keler T, Davis TA, Stupp R, Sampson JH, ACT IV trial investigators. PMID: 28844499.
      View in: PubMed   Mentions: 517     Fields:    Translation:HumansCTClinical Trials
    71. Probing the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in gliomas: A phase 2 study of everolimus for recurrent adult low-grade gliomas. Cancer. 2017 Dec 01; 123(23):4631-4639. Wahl M, Chang SM, Phillips JJ, Molinaro AM, Costello JF, Mazor T, Alexandrescu S, Lupo JM, Nelson SJ, Berger M, Prados M, Taylor JW, Butowski N, Clarke JL, Haas-Kogan D. PMID: 28759109; PMCID: PMC5693663.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCTClinical Trials
    72. Early tumor growth between initial resection and radiotherapy of glioblastoma: incidence and impact on clinical outcomes. J Neurooncol. 2017 Aug; 134(1):213-219. Villanueva-Meyer JE, Han SJ, Cha S, Butowski NA. PMID: 28567589; PMCID: PMC5563441.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    73. Targeted next-generation sequencing of pediatric neuro-oncology patients improves diagnosis, identifies pathogenic germline mutations, and directs targeted therapy. Neuro Oncol. 2017 05 01; 19(5):699-709. Kline CN, Joseph NM, Grenert JP, van Ziffle J, Talevich E, Onodera C, Aboian M, Cha S, Raleigh DR, Braunstein S, Torkildson J, Samuel D, Bloomer M, Campomanes AGA, Banerjee A, Butowski N, Raffel C, Tihan T, Bollen AW, Phillips JJ, Korn WM, Yeh I, Bastian BC, Gupta N, Mueller S, Perry A, Nicolaides T, Solomon DA. PMID: 28453743; PMCID: PMC5464451.
      View in: PubMed   Mentions: 136     Fields:    Translation:Humans
    74. The Effect of Molecular Diagnostics on the Treatment of Glioma. Curr Oncol Rep. 2017 Apr; 19(4):26. Bush NA, Butowski N. PMID: 28303493.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansAnimalsCells
    75. Chordoid glioma of the third ventricle: report of a rapidly progressive case. J Neurooncol. 2017 05; 132(3):487-495. Erwood AA, Velazquez-Vega JE, Neill S, Solomon DA, Butowski N, Nowlan A, Dunbar E, Brat DJ. PMID: 28315998.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    76. Association of early changes in 1H MRSI parameters with survival for patients with newly diagnosed glioblastoma receiving a multimodality treatment regimen. Neuro Oncol. 2017 03 01; 19(3):430-439. Nelson SJ, Kadambi AK, Park I, Li Y, Crane J, Olson M, Molinaro A, Roy R, Butowski N, Cha S, Chang S. PMID: 27576874; PMCID: PMC5464305.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    77. A phase 1 trial of intravenous liposomal irinotecan in patients with recurrent high-grade glioma. Cancer Chemother Pharmacol. 2017 03; 79(3):603-610. Clarke JL, Molinaro AM, Cabrera JR, DeSilva AA, Rabbitt JE, Prey J, Drummond DC, Kim J, Noble C, Fitzgerald JB, Chang SM, Butowski NA, Taylor JW, Park JW, Prados MD. PMID: 28233053.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCTClinical Trials
    78. Clinical trial endpoints for patients with gliomas. Neurooncol Pract. 2017 Dec; 4(4):201-208. Taylor JW, Molinaro AM, Butowski N, Prados M. PMID: 31385993; PMCID: PMC6655446.
      View in: PubMed   Mentions: 5  
    79. Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide. Neuro Oncol. 2017 02 01; 19(2):242-251. Wahl M, Phillips JJ, Molinaro AM, Lin Y, Perry A, Haas-Kogan DA, Costello JF, Dayal M, Butowski N, Clarke JL, Prados M, Nelson S, Berger MS, Chang SM. PMID: 27571885; PMCID: PMC5464133.
      View in: PubMed   Mentions: 54     Fields:    Translation:HumansCTClinical Trials
    80. Treatment options for recurrent high-grade gliomas. CNS Oncol. 2017 01; 6(1):61-70. Birk HS, Han SJ, Butowski NA. PMID: 28001091; PMCID: PMC6027924.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    81. Phase I study of RO4929097 with bevacizumab in patients with recurrent malignant glioma. J Neurooncol. 2016 12; 130(3):571-579. Pan E, Supko JG, Kaley TJ, Butowski NA, Cloughesy T, Jung J, Desideri S, Grossman S, Ye X, Park DM. PMID: 27826680; PMCID: PMC5571739.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCTClinical Trials
    82. Expression and prognostic impact of immune modulatory molecule PD-L1 in meningioma. J Neurooncol. 2016 12; 130(3):543-552. Han SJ, Reis G, Kohanbash G, Shrivastav S, Magill ST, Molinaro AM, McDermott MW, Theodosopoulos PV, Aghi MK, Berger MS, Butowski NA, Barani I, Phillips JJ, Perry A, Okada H. PMID: 27624915; PMCID: PMC5560602.
      View in: PubMed   Mentions: 56     Fields:    Translation:HumansCells
    83. Serial analysis of 3D H-1 MRSI for patients with newly diagnosed GBM treated with combination therapy that includes bevacizumab. J Neurooncol. 2016 10; 130(1):171-179. Nelson SJ, Li Y, Lupo JM, Olson M, Crane JC, Molinaro A, Roy R, Clarke J, Butowski N, Prados M, Cha S, Chang SM. PMID: 27535746; PMCID: PMC5069332.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    84. The Development of Reduced Diffusion Following Bevacizumab Therapy Identifies Regions of Recurrent Disease in Patients with High-grade Glioma. Acad Radiol. 2016 09; 23(9):1073-82. Barajas RF, Butowski NA, Phillips JJ, Aghi MK, Berger MS, Chang SM, Cha S. PMID: 27443507; PMCID: PMC5571825.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    85. Interventional MRI-guided catheter placement and real time drug delivery to the central nervous system. Expert Rev Neurother. 2016 06; 16(6):635-9. Han SJ, Bankiewicz K, Butowski NA, Larson PS, Aghi MK. PMID: 27054877; PMCID: PMC5553275.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    86. In Reply: Survival With Glioblastoma Multiforme and the Timing of Chemoradiation. Neurosurgery. 2016 Feb; 78(2):E315. Han SJ, Butowski NA. PMID: 26492432.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    87. Clinical outcome and prognostic factors for central neurocytoma: twenty year institutional experience. J Neurooncol. 2016 Jan; 126(1):193-200. Imber BS, Braunstein SE, Wu FY, Nabavizadeh N, Boehling N, Weinberg VK, Tihan T, Barnes M, Mueller S, Butowski NA, Clarke JL, Chang SM, McDermott MM, Prados MD, Berger MS, Haas-Kogan DA. PMID: 26493740; PMCID: PMC4826306.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    88. Association of Diffusion and Anatomic Imaging Parameters with Survival for Patients with Newly Diagnosed Glioblastoma Participating in Two Different Clinical Trials. Transl Oncol. 2015 Dec; 8(6):446-55. Wen Q, Jalilian L, Lupo JM, Li Y, Roy R, Molinaro AM, Chang SM, Prados M, Butowski N, Clarke J, Nelson SJ. PMID: 26692525; PMCID: PMC4700297.
      View in: PubMed   Mentions: 1  
    89. Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study. Neuro Oncol. 2016 Apr; 18(4):557-64. Butowski N, Colman H, De Groot JF, Omuro AM, Nayak L, Wen PY, Cloughesy TF, Marimuthu A, Haidar S, Perry A, Huse J, Phillips J, West BL, Nolop KB, Hsu HH, Ligon KL, Molinaro AM, Prados M. PMID: 26449250; PMCID: PMC4799682.
      View in: PubMed   Mentions: 291     Fields:    Translation:HumansCTClinical Trials
    90. Central Nervous System Cancers, Version 1.2015. J Natl Compr Canc Netw. 2015 Oct; 13(10):1191-202. Nabors LB, Portnow J, Ammirati M, Baehring J, Brem H, Brown P, Butowski N, Chamberlain MC, Fenstermaker RA, Friedman A, Gilbert MR, Hattangadi-Gluth J, Holdhoff M, Junck L, Kaley T, Lawson R, Loeffler JS, Lovely MP, Moots PL, Mrugala MM, Newton HB, Parney I, Raizer JJ, Recht L, Shonka N, Shrieve DC, Sills AK, Swinnen LJ, Tran D, Tran N, Vrionis FD, Weiss S, Wen PY, McMillian N, Engh AM. PMID: 26483059.
      View in: PubMed   Mentions: 55     Fields:    Translation:Humans
    91. Neurocognitive Function in Newly Diagnosed Low-grade Glioma Patients Undergoing Surgical Resection With Awake Mapping Techniques. Neurosurgery. 2015 Sep; 77(3):371-9; discussion 379. Racine CA, Li J, Molinaro AM, Butowski N, Berger MS. PMID: 25930064.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    92. Impact of Timing of Concurrent Chemoradiation for Newly Diagnosed Glioblastoma: A Critical Review of Current Evidence. Neurosurgery. 2015 Aug; 62 Suppl 1:160-5. Han SJ, Englot DJ, Birk H, Molinaro AM, Chang SM, Clarke JL, Prados MD, Taylor JW, Berger MS, Butowski NA. PMID: 26181937; PMCID: PMC5260825.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    93. The Effect of Timing of Concurrent Chemoradiation in Patients With Newly Diagnosed Glioblastoma. Neurosurgery. 2015 Aug; 77(2):248-53; discussion 253. Han SJ, Rutledge WC, Molinaro AM, Chang SM, Clarke JL, Prados MD, Taylor JW, Berger MS, Butowski NA. PMID: 25856113; PMCID: PMC4506198.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    94. The effects of anti-angiogenic therapy on the formation of radiation-induced microbleeds in normal brain tissue of patients with glioma. Neuro Oncol. 2016 Jan; 18(1):87-95. Lupo JM, Molinaro AM, Essock-Burns E, Butowski N, Chang SM, Cha S, Nelson SJ. PMID: 26206774; PMCID: PMC4677411.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    95. Epidemiology and diagnosis of brain tumors. Continuum (Minneap Minn). 2015 Apr; 21(2 Neuro-oncology):301-13. Butowski NA. PMID: 25837897.
      View in: PubMed   Mentions: 37     Fields:    Translation:Humans
    96. Central nervous system cancers, version 2.2014. Featured updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2014 Nov; 12(11):1517-23. Nabors LB, Portnow J, Ammirati M, Brem H, Brown P, Butowski N, Chamberlain MC, DeAngelis LM, Fenstermaker RA, Friedman A, Gilbert MR, Hattangadi-Gluth J, Hesser D, Holdhoff M, Junck L, Lawson R, Loeffler JS, Moots PL, Mrugala MM, Newton HB, Raizer JJ, Recht L, Shonka N, Shrieve DC, Sills AK, Swinnen LJ, Tran D, Tran N, Vrionis FD, Wen PY, McMillian NR, Ho M. PMID: 25361798; PMCID: PMC4337873.
      View in: PubMed   Mentions: 40     Fields:    Translation:Humans
    97. NT113, a pan-ERBB inhibitor with high brain penetrance, inhibits the growth of glioblastoma xenografts with EGFR amplification. Mol Cancer Ther. 2014 Dec; 13(12):2919-29. Yoshida Y, Ozawa T, Yao TW, Shen W, Brown D, Parsa AT, Raizer JJ, Cheng SY, Stegh AH, Mazar AP, Giles FJ, Sarkaria JN, Butowski N, Nicolaides T, James CD. PMID: 25313012; PMCID: PMC4364529.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimalsCells
    98. Clinical practice experience with NovoTTF-100A™ system for glioblastoma: The Patient Registry Dataset (PRiDe). Semin Oncol. 2014 Oct; 41 Suppl 6:S4-S13. Mrugala MM, Engelhard HH, Dinh Tran D, Kew Y, Cavaliere R, Villano JL, Annenelie Bota D, Rudnick J, Love Sumrall A, Zhu JJ, Butowski N. PMID: 25213869.
      View in: PubMed   Mentions: 78     Fields:    Translation:Humans
    99. Familial gliomas: cases in two pairs of brothers. J Neurooncol. 2015 Jan; 121(1):135-40. Osorio JA, Hervey-Jumper SL, Walsh KM, Clarke JL, Butowski NA, Prados MD, Berger MS. PMID: 25208478.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    100. A single-institution phase II trial of radiation, temozolomide, erlotinib, and bevacizumab for initial treatment of glioblastoma. Neuro Oncol. 2014 Jul; 16(7):984-90. Clarke JL, Molinaro AM, Phillips JJ, Butowski NA, Chang SM, Perry A, Costello JF, DeSilva AA, Rabbitt JE, Prados MD. PMID: 24637230; PMCID: PMC4057142.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansCTClinical Trials
    101. Phase II trial of 7 days on/7 days off temozolmide for recurrent high-grade glioma. Neuro Oncol. 2014 Sep; 16(9):1255-62. Han SJ, Rolston JD, Molinaro AM, Clarke JL, Prados MD, Chang SM, Berger MS, DeSilva A, Butowski NA. PMID: 24670608; PMCID: PMC4136897.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansCellsCTClinical Trials
    102. Characterization and management of dermatologic adverse events with the NovoTTF-100A System, a novel anti-mitotic electric field device for the treatment of recurrent glioblastoma. Semin Oncol. 2014 Jun; 41 Suppl 4:S1-14. Lacouture ME, Davis ME, Elzinga G, Butowski N, Tran D, Villano JL, DiMeglio L, Davies AM, Wong ET. PMID: 24794308.
      View in: PubMed   Mentions: 49     Fields:    Translation:Humans
    103. Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: a phase II, single-arm trial. Neuro Oncol. 2014 Jan; 16(2):274-9. Bloch O, Crane CA, Fuks Y, Kaur R, Aghi MK, Berger MS, Butowski NA, Chang SM, Clarke JL, McDermott MW, Prados MD, Sloan AE, Bruce JN, Parsa AT. PMID: 24335700; PMCID: PMC3895386.
      View in: PubMed   Mentions: 122     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    104. A roundtable discussion on the clinical challenges and options for the treatment of glioblastoma: introducing a novel modality, TTFields. Semin Oncol. 2013 Dec; 40(6):S2-4. Butowski N, Wong ET, Mehta MP, Wilson LK. PMID: 24331200.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    105. Central nervous system cancers. J Natl Compr Canc Netw. 2013 Sep 01; 11(9):1114-51. Nabors LB, Ammirati M, Bierman PJ, Brem H, Butowski N, Chamberlain MC, DeAngelis LM, Fenstermaker RA, Friedman A, Gilbert MR, Hesser D, Holdhoff M, Junck L, Lawson R, Loeffler JS, Maor MH, Moots PL, Morrison T, Mrugala MM, Newton HB, Portnow J, Raizer JJ, Recht L, Shrieve DC, Sills AK, Tran D, Tran N, Vrionis FD, Wen PY, McMillian N, Ho M, National Comprehensive Cancer Network. PMID: 24029126; PMCID: PMC4124889.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    106. Disseminated progression of glioblastoma after treatment with bevacizumab. Clin Neurol Neurosurg. 2013 Sep; 115(9):1795-801. Bloch O, Safaee M, Sun MZ, Butowski NA, McDermott MW, Berger MS, Aghi MK, Parsa AT. PMID: 23706614; PMCID: PMC5565209.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    107. Using susceptibility-weighted imaging to determine response to combined anti-angiogenic, cytotoxic, and radiation therapy in patients with glioblastoma multiforme. Neuro Oncol. 2013 Apr; 15(4):480-9. Lupo JM, Essock-Burns E, Molinaro AM, Cha S, Chang SM, Butowski N, Nelson SJ. PMID: 23393208; PMCID: PMC3607266.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    108. Comparing routes of delivery for nanoliposomal irinotecan shows superior anti-tumor activity of local administration in treating intracranial glioblastoma xenografts. Neuro Oncol. 2013 Feb; 15(2):189-97. Chen PY, Ozawa T, Drummond DC, Kalra A, Fitzgerald JB, Kirpotin DB, Wei KC, Butowski N, Prados MD, Berger MS, Forsayeth JR, Bankiewicz K, James CD. PMID: 23262509; PMCID: PMC3548589.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansAnimalsCells
    109. Endpoints for clinical trials and revised assessment in neuro-oncology. Curr Opin Neurol. 2012 Dec; 25(6):780-5. Butowski N, Chang SM. PMID: 23007010.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    110. Individual patient-specific immunity against high-grade glioma after vaccination with autologous tumor derived peptides bound to the 96 KD chaperone protein. Clin Cancer Res. 2013 Jan 01; 19(1):205-14. Crane CA, Han SJ, Ahn B, Oehlke J, Kivett V, Fedoroff A, Butowski N, Chang SM, Clarke J, Berger MS, McDermott MW, Prados MD, Parsa AT. PMID: 22872572.
      View in: PubMed   Mentions: 103     Fields:    Translation:HumansCellsCTClinical Trials
    111. Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors. J Clin Oncol. 2012 Jul 01; 30(19):2307-13. Krop I, Demuth T, Guthrie T, Wen PY, Mason WP, Chinnaiyan P, Butowski N, Groves MD, Kesari S, Freedman SJ, Blackman S, Watters J, Loboda A, Podtelezhnikov A, Lunceford J, Chen C, Giannotti M, Hing J, Beckman R, Lorusso P. PMID: 22547604.
      View in: PubMed   Mentions: 160     Fields:    Translation:HumansCTClinical Trials
    112. Neurosurgical management and prognosis of patients with glioblastoma that progresses during bevacizumab treatment. Neurosurgery. 2012 Feb; 70(2):361-70. Clark AJ, Lamborn KR, Butowski NA, Chang SM, Prados MD, Clarke JL, McDermott MW, Parsa AT, Berger MS, Aghi MK. PMID: 21841523.
      View in: PubMed   Mentions: 37     Fields:    Translation:Humans
    113. General and neurological complications of targeted therapy. Handb Clin Neurol. 2012; 105:937-45. Butowski NA, Chang SM. PMID: 22230543.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    114. Conditional probability of survival in patients with newly diagnosed glioblastoma. J Clin Oncol. 2011 Nov 01; 29(31):4175-80. Polley MY, Lamborn KR, Chang SM, Butowski N, Clarke JL, Prados M. PMID: 21969507; PMCID: PMC3208537.
      View in: PubMed   Mentions: 32     Fields:    Translation:Humans
    115. Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma. Neuro Oncol. 2011 Dec; 13(12):1331-8. Butowski N, Chang SM, Lamborn KR, Polley MY, Pieper R, Costello JF, Vandenberg S, Parvataneni R, Nicole A, Sneed PK, Clarke J, Hsieh E, Costa BM, Reis RM, Hristova-Kazmierski M, Nicol SJ, Thornton DE, Prados MD. PMID: 21896554; PMCID: PMC3223090.
      View in: PubMed   Mentions: 43     Fields:    Translation:HumansCellsCTClinical Trials
    116. Anti-angiogenic therapy in glioma. Clin Transl Oncol. 2011 May; 13(5):294-300. Butowski N. PMID: 21596656.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    117. Central nervous system cancers. J Natl Compr Canc Netw. 2011 Apr; 9(4):352-400. Brem SS, Bierman PJ, Brem H, Butowski N, Chamberlain MC, Chiocca EA, DeAngelis LM, Fenstermaker RA, Friedman A, Gilbert MR, Hesser D, Junck L, Linette GP, Loeffler JS, Maor MH, Michael M, Moots PL, Morrison T, Mrugala M, Nabors LB, Newton HB, Portnow J, Raizer JJ, Recht L, Shrieve DC, Sills AK, Vrionis FD, Wen PY, National Comprehensive Cancer Network. PMID: 21464144.
      View in: PubMed   Mentions: 44     Fields:    Translation:Humans
    118. Identifying the needs of brain tumor patients and their caregivers. J Neurooncol. 2011 Sep; 104(3):737-44. Parvataneni R, Polley MY, Freeman T, Lamborn K, Prados M, Butowski N, Liu R, Clarke J, Page M, Rabbitt J, Fedoroff A, Clow E, Hsieh E, Kivett V, Deboer R, Chang S. PMID: 21311950; PMCID: PMC3170122.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    119. Medical management of brain metastases. Neurosurg Clin N Am. 2011 Jan; 22(1):27-36, v-vi. Butowski N. PMID: 21109146.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    120. Impact of bevacizumab chemotherapy on craniotomy wound healing. J Neurosurg. 2011 Jun; 114(6):1609-16. Clark AJ, Butowski NA, Chang SM, Prados MD, Clarke J, Polley MY, Sughrue ME, McDermott MW, Parsa AT, Berger MS, Aghi MK. PMID: 21142749.
      View in: PubMed   Mentions: 33     Fields:    Translation:Humans
    121. Assessment of perfusion MRI-derived parameters in evaluating and predicting response to antiangiogenic therapy in patients with newly diagnosed glioblastoma. Neuro Oncol. 2011 Jan; 13(1):119-31. Essock-Burns E, Lupo JM, Cha S, Polley MY, Butowski NA, Chang SM, Nelson SJ. PMID: 21036812; PMCID: PMC3018901.
      View in: PubMed   Mentions: 31     Fields:    Translation:Humans
    122. Evaluation of diffusion parameters as early biomarkers of disease progression in glioblastoma multiforme. Neuro Oncol. 2010 Sep; 12(9):908-16. Khayal IS, Polley MY, Jalbert L, Elkhaled A, Chang SM, Cha S, Butowski NA, Nelson SJ. PMID: 20501631; PMCID: PMC2940691.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    123. Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02). Neuro Oncol. 2010 Aug; 12(8):855-61. Iwamoto FM, Lamborn KR, Robins HI, Mehta MP, Chang SM, Butowski NA, Deangelis LM, Abrey LE, Zhang WT, Prados MD, Fine HA. PMID: 20200024; PMCID: PMC2940686.
      View in: PubMed   Mentions: 98     Fields:    Translation:HumansCTClinical Trials
    124. Recent advances in therapy for glioblastoma. Arch Neurol. 2010 Mar; 67(3):279-83. Clarke J, Butowski N, Chang S. PMID: 20212224.
      View in: PubMed   Mentions: 124     Fields:    Translation:Humans
    125. Enzastaurin plus temozolomide with radiation therapy in glioblastoma multiforme: a phase I study. Neuro Oncol. 2010 Jun; 12(6):608-13. Butowski N, Chang SM, Lamborn KR, Polley MY, Parvataneni R, Hristova-Kazmierski M, Musib L, Nicol SJ, Thornton DE, Prados MD. PMID: 20156802; PMCID: PMC2940647.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCTClinical Trials
    126. Immunostimulants for malignant gliomas. Neurosurg Clin N Am. 2010 Jan; 21(1):53-65. Butowski N. PMID: 19944966.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimals
    127. Six-month progression-free survival as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma patients receiving temozolomide. Neuro Oncol. 2010 Mar; 12(3):274-82. Polley MY, Lamborn KR, Chang SM, Butowski N, Clarke JL, Prados M. PMID: 20167815; PMCID: PMC2940590.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCTClinical Trials
    128. Integration of preoperative anatomic and metabolic physiologic imaging of newly diagnosed glioma. J Neurooncol. 2009 May; 92(3):401-15. Chang SM, Nelson S, Vandenberg S, Cha S, Prados M, Butowski N, McDermott M, Parsa AT, Aghi M, Clarke J, Berger M. PMID: 19357966; PMCID: PMC2834319.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    129. Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. J Clin Oncol. 2009 Feb 01; 27(4):579-84. Prados MD, Chang SM, Butowski N, DeBoer R, Parvataneni R, Carliner H, Kabuubi P, Ayers-Ringler J, Rabbitt J, Page M, Fedoroff A, Sneed PK, Berger MS, McDermott MW, Parsa AT, Vandenberg S, James CD, Lamborn KR, Stokoe D, Haas-Kogan DA. PMID: 19075262; PMCID: PMC2645859.
      View in: PubMed   Mentions: 168     Fields:    Translation:HumansCTClinical Trials
    130. Preoperative prognostic classification system for hemispheric low-grade gliomas in adults. J Neurosurg. 2008 Nov; 109(5):817-24. Chang EF, Smith JS, Chang SM, Lamborn KR, Prados MD, Butowski N, Barbaro NM, Parsa AT, Berger MS, McDermott MM. PMID: 18976070.
      View in: PubMed   Mentions: 72     Fields:    Translation:Humans
    131. A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas. J Neurooncol. 2009 Jan; 91(2):183-9. Butowski N, Lamborn KR, Lee BL, Prados MD, Cloughesy T, DeAngelis LM, Abrey L, Fink K, Lieberman F, Mehta M, Ian Robins H, Junck L, Salazar AM, Chang SM. PMID: 18850068; PMCID: PMC3104130.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansCTClinical Trials
    132. A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05). J Neurooncol. 2009 Jan; 91(2):175-82. Butowski N, Chang SM, Junck L, DeAngelis LM, Abrey L, Fink K, Cloughesy T, Lamborn KR, Salazar AM, Prados MD. PMID: 18797818; PMCID: PMC4779120.
      View in: PubMed   Mentions: 58     Fields:    Translation:HumansCTClinical Trials
    133. Quality of life in low-grade glioma patients receiving temozolomide. Neuro Oncol. 2009 Feb; 11(1):59-68. Liu R, Solheim K, Polley MY, Lamborn KR, Page M, Fedoroff A, Rabbitt J, Butowski N, Prados M, Chang SM. PMID: 18713953; PMCID: PMC2718960.
      View in: PubMed   Mentions: 30     Fields:    Translation:Humans
    134. Longitudinal magnetic resonance imaging features of glioblastoma multiforme treated with radiotherapy with or without brachytherapy. Int J Radiat Oncol Biol Phys. 2008 Dec 01; 72(5):1340-6. Aiken AH, Chang SM, Larson D, Butowski N, Cha S. PMID: 18538496.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    135. Historical controls for phase II surgically based trials requiring gross total resection of glioblastoma multiforme. J Neurooncol. 2007 Oct; 85(1):87-94. Butowski N, Lamborn KR, Berger MS, Prados MD, Chang SM. PMID: 17457513.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    136. Therapeutic advances for glioblastoma multiforme: current status and future prospects. Curr Oncol Rep. 2007 Jan; 9(1):66-70. Robins HI, Chang S, Butowski N, Mehta M. PMID: 17164050.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    137. Standard treatment and experimental targeted drug therapy for recurrent glioblastoma multiforme. Neurosurg Focus. 2006 Apr 15; 20(4):E4. Chang SM, Butowski NA, Sneed PK, Garner IV. PMID: 16709035.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    138. Diagnosis and treatment of recurrent high-grade astrocytoma. J Clin Oncol. 2006 Mar 10; 24(8):1273-80. Butowski NA, Sneed PK, Chang SM. PMID: 16525182.
      View in: PubMed   Mentions: 73     Fields:    Translation:Humans
    139. Glial tumors: the current state of scientific knowledge. Clin Neurosurg. 2006; 53:106-13. Butowski NA, Chang SM. PMID: 17380744.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    140. Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma. Neuro Oncol. 2006 Jan; 8(1):67-78. Prados MD, Lamborn KR, Chang S, Burton E, Butowski N, Malec M, Kapadia A, Rabbitt J, Page MS, Fedoroff A, Xie D, Kelley SK. PMID: 16443950; PMCID: PMC1871925.
      View in: PubMed   Mentions: 83     Fields:    Translation:HumansCTClinical Trials
    141. GNOSIS: guidelines for neuro-oncology: standards for investigational studies-reporting of phase 1 and phase 2 clinical trials. Neuro Oncol. 2005 Oct; 7(4):425-34. Chang SM, Reynolds SL, Butowski N, Lamborn KR, Buckner JC, Kaplan RS, Bigner DD. PMID: 16212807; PMCID: PMC1871726.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    142. A phase II study of concurrent temozolomide and cis-retinoic acid with radiation for adult patients with newly diagnosed supratentorial glioblastoma. Int J Radiat Oncol Biol Phys. 2005 Apr 01; 61(5):1454-9. Butowski N, Prados MD, Lamborn KR, Larson DA, Sneed PK, Wara WM, Malec M, Rabbitt J, Page M, Chang SM. PMID: 15817350.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCTClinical Trials
    143. Small molecule and monoclonal antibody therapies in neurooncology. Cancer Control. 2005 Apr; 12(2):116-24. Butowski N, Chang SM. PMID: 15855895.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    Nicholas's Networks
    Concepts (325)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (132)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSF Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).

    We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use. This site is running Profiles RNS version UCSF-v3.1.0-5-g94c7c43e on PROFILES-PWEB04.

    Copyright © The Regents of the University of California.